Finally, the integration of the Swiss business of Banca Svizzera Italiana (BSI) into EFG Bank has been completed. From this moment, the majority of the customer relationships and employees of BSI are transferred, as EFG referred in a media release. The combined business will now be launched on the market under the name EFG. EFG International said it completed the legal integration of "substantially all" of BSI SA's Swiss business into EFG Bank AG, a 100 percent subsidiary of EFG International. The remaining BSI entities in Luxembourg and Monaco are expected to be integrated in the course of the second quarter of 2017, EFG said.
US regulators have agreed to a Chinese conglomerate’s proposed $43 billion acquisition of Swiss agribusiness giant Syngenta on condition it sells some businesses to satisfy anti-monopoly objections. China National Chemical and Switzerland's Syngenta have agreed to divest three types of pesticides in order to win U.S. Federal Trade Commission approval for their $43 billion merger, the largest ever overseas acquisition by a Chinese company. A U.S. national security panel cleared the deal in August 2016, despite concerns among some lawmakers and farmers about China's influence in U.S. food production.
The merger between the Deutsche Börse and the London Stock Exchange has been vetoed by the European Commission because of competition concerns, ending a third attempt in 17 years to unite the financial hubs of London and Frankfurt. In a statement on Wednesday, EU Competition Commissioner Margrethe Vestager said Britain's decision to leave the 28-nation bloc had played no role in banning the tie-up.
A senior executive at Credit Suisse Taiwan Elsa Chiu and her husband were released on bail early Wednesday after being interrogate about alleged insider trading in the takeover of Hermes Microvision by ASML of the Netherlands, Taipei District Prosecutors Office spokesman Chang Chieh-Chin told Reuters. "During the merger and acquisition activities, there were some trading irregularities, and the stock exchange regulator detected this irregular trading," said Chang, who is also a deputy chief prosecutor.
French drugmaker Sanofi and Swiss manufacturer Lonza, a supplier to the pharmaceutical, healthcare and life-science industries, announced Monday that they have entered into a strategic partnership to establish a large-scale biologics production facility in Switzerland. The initial investment will be around 290 million Swiss francs (€270 million), to be split equally between each company. Pending regulatory approvals, the facility, through a 50-50 joint venture, will be located in Visp, Switzerland, Sanofi and Lonza said in a joint statement. The initial phase of the facility will commence construction in 2017, it is expected to be fully operational by 2020.
PSA Group is discussing a potential acquisition of rival European carmaker Opel from General Motors, a spokesman for the French automaker said on Tuesday. "PSA confirms that it is exploring a number of strategic initiatives with GM with the aim of increasing its profitability and operating efficiency, including a potential acquisition of Opel," company spokesman Bertrand Blaise said.
Lastminute.com strengthens its presence in Italy by signing agreement with Travel Holding to acquire Gartour, an italian leading incoming tour operator. The latter, according to the agreements made by the parties, will continue its activities under a renewable contract of lease for a period of twelve months, before passing definitively under Lastminute.com. Gartour currently employs about 130 people for a turnover of €35 million in 2016.
Swiss pesticides and seeds group Syngenta reported 2016 earnings before interest, tax, depreciation and amortisation (EBITDA) of $2.66 billion on sales of $12.79 billion. Analysts polled by Reuters had on average expected EBITDA to fall 5.9 percent to $2.61 billion on sales down 4.2 percent to $12.85 billion. They had expected it to boost its dividend to 11.60 Swiss francs from 11.00
Johnson & Johnson will buy Swiss drugmaker Actelion in a $30 billion deal that both secures promising research and bolsters the product portfolio controlled by the U.S. health care giant. The deal between the world's biggest producer of healthcare goods and Actelion, a leader in medicines treating high blood pressure, will create a new Swiss-listed firm called R&D NewCo focusing on the research and development of new drugs, the two companies said in a joint statement. The U.S. conglomerate will then buy Actelion's seven drugs that are currently on the market and two potential treatments in late-stage testing. The acquisition gives J&J access to the Swiss group’s line-up of high-price, high-margin medicines for rare diseases, helping it diversify its drug portfolio as its biggest product.
Yahoo says its closing its Verizon deal in the second quarter instead of in the first quarter, which is when it initially said the deal would close. The $4.8 billion deal was originally slated to close in the first quarter, but that was before Yahoo reported two massive data breaches that analysts say may scrap the entire deal. Although Yahoo continues to work to close the acquisition, there’s still work required to meet closing the deal's closing conditions, the company said in an earnings statement, without elaborating.
Startups need to build a growth plan and exit path early in their life cycle to unlock the value cre
Molti investitori istituzionali stanno iniziando a prendere sempre più in considerazione anche le m
The Responsible Finance Institute (RFI) Foundation and the Swiss Arab Network organize the RFI Summi
FinLantern is glad to invite you to a “Sustainable Apero”
Presentazione di una piattaforma omnicanale per aziende con centralini, call center o contact center
Updates and news from MarketPlus
|SMI® PR||8812.67||-0,36 %|
|LYXOR DAX INAV||118.957||-0,07 %|
|FTSE MIB Index||20609.16||0,06 %|
|FTSE 100||7203.94||-0,46 %|
|CAC 40||5267.33||-0,08 %|
|S&P 500||2384.20||-0,19 %|
|NASDAQ Composite||6047.61||-0,02 %|
|HANG SENG INDEX||24615.13||-0,34 %|
|Powered by Yahoo Finance|